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Abstract
Background: Insufficient cost data and limited capacity constrains the understanding of the actual resources required
for effective TB control. This study used process maps and time-driven activity-based costing to document TB service
delivery processes. The analysis identified the resources required to sustain TB services in Zimbabwe, as well as several
opportunities for more effective and efficient use of available resources.
Methods: A multi-disciplinary team applied time-driven activity-based costing (TDABC) to develop process maps and
measure the cost of clinical pathways used for Drug Susceptible TB (DS-TB) at urban polyclinics, rural district and
provincial hospitals, and community based targeted screening for TB (Tas4TB). The team performed interviews and
observations to collect data on the time taken by health care worker-patient pairs at every stage of the treatment
pathway. The personnel’s practical capacity and capacity cost rates were calculated on five cost domains. An MS Excel
model calculated diagnostic and treatment costs.
Findings: Twenty-five stages were identified in the TB care pathway across all health facilities except for community
targeted screening for TB. Considerable variations were observed among the facilities in how health care professionals
performed client registration, taking of vital signs, treatment follow-up, dispensing medicines and processing samples.
The average cost per patient for the entire DS-TB care was USD324 with diagnosis costing USD69 and treatment
costing USD255. The average cost for diagnosis and treatment was higher in clinics than in hospitals (USD392 versus
USD256). Nurses in clinics were 1.6 time more expensive than in hospitals. The main cost components were personnel
(USD130) and laboratory (USD119). Diagnostic cost in Tas4TB was twice that of health facility setting (USD153 vs
USD69), with major cost drivers being demand creation (USD89) and sputum specimen transportation (USD5 vs USD3).
(Continued on next page)
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Bertha.Simwaka@theglobalfund.org
2The Global Fund to Fight TB, HIV and Malaria, Global Health Campus,
Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland
Full list of author information is available at the end of the article
Chirenda et al. BMC Health Services Research          (2021) 21:242 
https://doi.org/10.1186/s12913-021-06212-x
(Continued from previous page)
Conclusion: TDABC is a feasible and effective costing and management tool in low-resource settings. The TDABC
process maps and treatment costs revealed several opportunities for innovative improvements in the NTP under public
health programme settings. Re-engineering laboratory testing processes and synchronising TB treatment follow-up
with antiretroviral treatments could produce better and more uniform TB treatments at significantly lower cost in Zimbabwe.
Keywords: Tuberculosis, Pathway to care cycles, Provider cost, Time driven activity-based costing
Background
In 2018, Zimbabwe had an estimated Tuberculosis (TB)
incidence rate of 210/100,000 population, more than the
global average of 130/100,000. Zimbabwe was among
the 14 countries with a triple-burden of TB, Tubercu-
losis/Human immunodeficiency virus (TB/HIV), and
multi-drug resistant TB (MDR-TB) [1]. The country had
a high TB and HIV co-infection rate of 62% and a treat-
ment coverage of 83% [2]. With nearly one-fifth of
undetected TB cases acting as foci for community trans-
mission, innovative TB case finding approaches remain
were an urgent priority.
Despite high-level political commitment to raise
USD15 billion annually for the global TB response,
only USD6·9 billion was available from both domestic
and international donors in 2018 [3, 4]. In the
Zimbabwe context, poor economic performance led to
a funding shortfall of more than USD67 million (69%)
for meeting the National Tuberculosis Programme
(NTP) Strategy Funding requirement for 2017–2020.
Despite the funding shortfall, Zimbabwe achieved
relatively high treatment coverage of more than 80%.
But donors were concerned about the robustness of
the costing for NTP’s 2017–2020 strategy. The lack of
valid data on TB delivery costs led to incorrect pro-
jections and limited optimisation of available re-
sources. This triggered a desire to better measure and
understand TB program costs, identify areas that
needed improvement in implementation, and guide
resource allocation. We applied time driven activity-
based costing (TDABC) to calculate the costs of ac-
tual healthcare resources used to diagnose and treat
TB patients [5–7]. This bottom-up approach, which
has had limited application to date in low-income set-
tings, contrasts with the top-down volume-based cost
allocation methods used previously in most health set-
tings. This paper illustrates the feasibility of applying
TDABC in a low-income setting for costing the care path-
way for DS-TB. The study was approved by the Medical
Research Council of Zimbabwe (MRCZ/A/2393).
Methods
Program set-up
The DS-TB care pathway started with a presumptive TB
patient’s initial contact and confirmation as a TB case at
the health facility and continued through successful
treatment completion. A molecular test using Cepheid
GeneXpert was used for the initial diagnosis of all pre-
sumptive TB cases. Smear microscopy was used only for
treatment monitoring. In 2018, only 125 GeneXpert
machines were available for the more than 1000
health facilities in Zimbabwe. Facilities without access
to GeneXpert machines relied on private couriers or
motorised Environmental Health Technicians (EHTs)
to transport sputum sample. A medical officer used
chest X-rays for bacteriologically negative but clinic-
ally unwell patients to either confirm TB diagnosis or
discharge the patient.
Since 2017, Zimbabwe had been using chest X-rays, as
a more sensitive initial TB screening tool (Tas4TB)
compared to symptoms assessment alone for screening
hard-to-reach and high burden populations. Tas4TB was
introduced initially in 21 high-burden but low notifying
districts. In 2018, Zimbabwe introduced bi-directional
screening for diabetes and TB. In this study, facility
based TB diagnosis and treatment, was defined as the
standard of care.
The treatment regimen for DS-TB consisted of rifam-
picin (R), isoniazid (H), pyrazinamide (Z) and etham-
butol (E) for two (2) months, followed by RH for four
(4) months (2RHZE/4RH). Confirmed TB patients were
required to visit the health facility once every 2 weeks to
collect medicines and assess treatment efficacy. At 2–3
months, 5 and 6months, repeat sputum specimens were
collected as part of treatment monitoring and to confirm cure.
Study sites
We selected nine (9) health facilities (study sites), con-
sidering disease burden and level of care managed by ei-
ther the Ministry of Health and Child Care (MoHCC) or
the Ministry of Local Government. Two provincial hos-
pitals (Chinhoyi and Gwanda), two district hospitals
(Maphisa and Banket), four urban polyclinics (Rutsa-
nana, Dzivarasekwa, Mzilikazi and Princess Margaret)
and one Tas4TB mobile clinic were selected for the study.
Costing approach and implementation
A multidisciplinary team from NTP, University of
Zimbabwe, College of Health Sciences, (UZCHS), Price
Waterhouse Coopers Advisory Services (PWC), Harvard
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Business School (HBS) and the Global Fund (GF) con-
ducted the study using TDABC. Capacity building was
achieved through training of national partners on
TBABC, joint development of process maps and tools,
and pilot testing facilitated by GF and HBS.
Process maps for TB care pathways were developed
iteratively using a combination of diagnostic algo-
rithms, observations of workflows at the facilities and
discussions with health care workers. Diagnostic maps
captured the care pathway processes from the time a
patient presented with signs and symptoms to con-
firmation of TB. Treatment maps captured the patient
care pathway processes from notification of a con-
firmed TB case to completion of recommended treat-
ment, which is, 6 months for DS-TB. Tas4TB maps
described the process from site identification, demand
creation, TB symptom screen using a WHO symptom
screening tool, digital chest X-ray, Xpert MTB/Rif
tests for presumptive cases, and treatment initiation
in communities.
We observed health care workers providing TB care
services at different TB care pathway stages, and doc-
umented the personnel type performing the task and
the time taken per stage as described by Kaplan and
Porter [7].
The USD/minute capacity cost rate (CCR) was mea-
sured for each resource type at a clinic (personnel or
equipment) by dividing the annual cost of the re-
source by its annual practical capacity. Practical cap-
acity calculation for personnel was based on five
working days per week for each health care worker
adjusted to exclude days used for vacation, continuing
professional development, sick leave and health
breaks. The team estimated number of minutes avail-
able each day of each personnel type, and multiplied
this quantity by number of working days per year to
obtain the total minutes available per year per person.
Salary data for each cadre of health care worker was
obtained from the HR Departments in the MoHCC
and Local Government Authorities.
A similar method was used to calculate the CCRs for
equipment and space. We assumed equipment
utilization of 85% with 15% down time for repairs, main-
tenance, and scheduled calibrations [8]. Cost of equip-
ment was based on most recent procurement data
supported by government or donors and useful life of
equipment. Useful life of equipment was estimated as
10 years for X-ray machines and vans; 5 years for Gen-
eXpert, full blood count, chemistry and audiometer, and
7 years for the digital X-ray machines.
We measured square metres within a health facility
dedicated to delivering TB care and time taken to pro-
vide TB services. In case of shared space, estimates were
used. Cost of space was based on replacement cost per
square metre, useful life (depreciation), plus annual op-
erating expenses as defined in the MoHCC guidelines
and costing of the National Health Strategy (NHS),
2015–2020.
Time taken by personnel or equipment at each step of
the process map was measured for individual patients and
averaged to calculate the average time per patient for each
activity step. This time was then multiplied by the
personnel or equipment’s capacity cost rate (CCR) to cal-
culate the resource’s cost to perform each treatment step.
In addition to the cost of human resources (HR)
and equipment, the analysis calculated the costs of
utilities (water and electricity supply), medicines, in-
cluding anti-TB medicines, laboratory supplies, and
other consumables using data from the facilities and
the NTP at central level. The overhead cost related to
program coordination by the NTP Unit within
MoHCC, was assumed to be independent of the
quantity and mix of patients treated and was excluded
from the analysis.
The final calculated provider unit costs per patient,
measured in United States Dollars (USD), were aggre-
gated by cost domain and facility. Using the cost of diag-
nosis and treatment of one TB patient per facility, we
estimated the total cost per facility using routinely re-
ported facility data for 2017. This assessed cost variation
by facility.
Data collection and management
The study was conducted from August 2018 to January
2019. The project team trained registered nurses, at each
TB facility, to be the research assistants (RA) to collect
data. The RAs were assigned to facilities away from their
usual workstations to minimise bias. Training and super-
vision of data collection were provided by the central team
of experts from the NTP, UZCHS, PwC, HBS and GF.
Data collection tools were pre-tested in four non-
participating facilities, two rural and two urban. One of
the rural facilities was a district hospital. The tools were
adjusted accordingly after the pilot and before field
work. The tools were programmed and uploaded into
REDCap (Research Electronic Data Capture; https://
projectredcap.org/software/), a data collection, transmit-
tal and storage open source software. Data were trans-
mitted electronically to the central level where the study
biostatistician provided data quality checks and appro-
priate feedback to the RAs.
Study participants
Health care workers (HCWs) and facility managers from
two provincial hospitals, two district hospitals and four
clinics, were interviewed as key informants. All the four
clinics were from the two metropolitan cities of Harare,
the capital city and Bulawayo, the second largest city in
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Zimbabwe. These were high volume facilities that en-
sured adequate tuberculosis patients to interview until
saturation. Each HCW-patient pair was observed during
diagnosis, care, and treatment to collect information on
time and resources used step by step. We observed 3 to 7
HCW-patient pairs to reach saturation and get an optimal
average time for each stage. Informed consent was
obtained from all research participants including patients.
Results
Six hundred and seventy (670) observations for health
care worker-patient pairs were conducted across nine
sites. We interviewed 116 key informants.
Availability of TB services by facility
All four hospitals had capacity to offer chest X-ray,
Xpert MTB/Rif/Ultra, full blood count, and chemistry
services. One urban clinic, Dzivarasekwa, had a GeneX-
pert machine. The three clinics without GeneXpert ma-
chines transported sputum specimen to nearest
GeneXpert sites. All facilities had microscopy services
for treatment monitoring. Facilities with no X-ray,
chemistry and full blood count services referred patients
to hospitals offering the services. Hospitals provided en-
tire cascade of care from diagnosis, treatment follow-up,
to treatment outcomes evaluation. Integrated TB/HIV
services were available in all sites (Table 1). The Tas4TB
Table 1 Equipment availability (TB Services) by facility, Zimbabwe TDABC, 2018
Banket Chinhoyi Dzivarasekwa Gwanda Maphisa Mzilikazi Princess Margaret Rutsa-nana Tas4TB
Digital CXR 1 2 0 1 1 0 0 0 3
GeneXpert 1 GX4 1 GX4 1 GX4 1 GX4 1 GX4 0 0 0 3 GX4
FBC Machine 2 3 0 2 2 0 0 0 0
Chemistry Analyser 1 3 0 2 1 0 0 0 0
Microscope 1 2 1 2 2 3 0 1 4
TSH Machine 0 1 0 1 0 0 0 0 0
Audiometry Machine 0 1 0 0 0 0 0 0 0
TB Mobile Van 0 0 0 0 0 0 0 0 1
Fig. 1 Primary care facility (clinic) TB Standard of Care pathway, 2018. HIV=Human immune-deficiency virus; DM = Diabetes mellitus; EHT =
Environmental health technician; TB = Tuberculosis; Vitals (BP=Blood Pressure; Ht = Height; Wt =Weight; Temp = Temperature);
Lab = Laboratory; +ve = Positive
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used a mobile van equipped with chest X-ray machines
for TB screening. Clients who were positive on chest x-
ray and symptom screen, had sputum collected and
referred to nearest facility with GeneXpert machine.
Diagnosis, treatment and care pathways for DSTB
Twenty-five stages of the care pathway were identified
from the process maps. The stages were relatively similar
across facilities except for Tas4TB (Figs. 1, 2, 3, 4 and 5).
Community Tas4TB included demand creation stage
and excluded treatment follow-up. All TB confirmed pa-
tients diagnosed through Tas4TB were referred to the
nearest facility for treatment follow up.
The different facilities had considerable variations in
the personnel types that performed registration, vital
signs, treatment follow-up, medicines dispensing and
sample processing (Tables 2 and 3). Table 2 shows that
a clerk performed the patient registration service. In all
facilities, a nurse provided initial and second consulta-
tions. However, third consultation, was almost always
done by the medical officer. Table 3 shows that nurses
provided most of the services, except for laboratory test-
ing performed by a laboratory scientist or technologist.
Five facilities used nurse aides, and four facilities used
nurses for vital signs. Diabetes Mellitus (DM) and HIV
testing were embedded in the diagnosis stage care cycle.
Sub-contracted private courier performed sample trans-
portation in Harare City; EHTs did this task at all other
facilities. After treatment initiation, the nurse
reviewed DSTB patients and monitored adverse drug
events every 2 weeks for 6 months during appointments
scheduled for patients'drug pick up. The last treatment
monitoring follow-up review was done by medical offi-
cers to assess treatment outcome status.
Average time spent on each stage by facility type
Sample processing and transportation and HIV testing
required the longest average times for health care
workers, range, 64–110 (Table 4). Hospitals took more
time processing samples and testing for HIV compared
to clinics. The services with the least times were regis-
tration and vital signs, range 0.9–2.6 and 3–3.7 respect-
ively. Tas4TB, used in remote locations far from
GeneXpert sites, had longer sample transportation (75
min) than district hospitals (69 min) and clinics (55
min). The recording and reporting of data, as well as
treatment initiation took much longer in Tas4TB than
in standard of care (10 vs 4 and 16 vs 4 respectively).
Fig. 2 Hospital TB standard of care pathway, Zimbabwe TDABC, 2018. HIV=Human immune-deficiency virus; DM = Diabetes mellitus; EHT =
Environmental health technician; TB = Tuberculosis; Vitals (BP=Blood Pressure; Ht = Height; Wt =Weight; Temp = Temperature); Lab = Laboratory;
+ve = Positive
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Fig. 3 TB Treatment follow-up pathway, (Clinic and Hospital) 2018. EHT = Environmental health technician; TB = Tuberculosis; BP=Blood Pressure;
Ht = Height; Wt =Weight; Temp = Temperature; Lab = Laboratory; DSTB = drug sensitive TB; DRTB = drug resistant TB; U&E + Creat = urea and
electrolytes + creatinine; ECG = electrocardiogram; FU = follow up; qns = questions; LFT = liver function test; TSH = thyroid stimulating hormone
Fig. 4 Tas4TB Demand creation TB Case finding pathway, Zimbabwe TDABC, 2018
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First consultation during diagnosis phase was longer in
clinics compared to both Tas4TB and hospitals (8 vs 2
vs 6) respectively. Tas4TB, a new concept in Zimbabwe,
used a recording and reporting tool with 66 variables
that took longer to complete than the reporting at the
other three settings. There were no variations in time
taken by presence of co-morbidities or gender across all
the stages and DM testing. The average time for HIV
testing was high in district hospitals compared to both
urban clinics and hospitals. Efficiencies were realized for
patients with known comorbid conditions (such as HIV)
since they did not need separate counselling and testing
sessions for those conditions.
Space and equipment capacity cost rate, Zimbabwe
TDABC, 2018
Table 5, shows the different cost capacity rates of the
space used to provide TB services by facility and type of
activities being performed. The consulting rooms for
hospitals had higher space CCR compared to clinics.
Capacity cost rates for waiting area, laboratory, and
pharmacy were the highest across all facilities. Chinhoyi
Hospital had the highest CCR for waiting area
(USD0·98), pharmacy (USD0·105) and laboratory
(USD0·145). The waiting area CCR for Dzivarasekwa
clinic was similar to that of Maphisa and Banket district
hospitals, USD0·05. In other clinics, some TB care activ-
ities were being provided in the same space, for example,
waiting area and first consulting rooms. Tas4TB had the
lowest space CCR of all facilities. Capacity cost rate for
GeneXpert was USD0·05 and USD0·19 for chest X-ray·
The most expensive equipment per patient was the TB
mobile van, with a CCR of USD0·57, given the added
fuel and vehicle costs.
The cost of care for DS-TB
The average cost per patient of the entire care pathway
was USD324 for all facilities (Table 6). The average cost
was higher in clinics (USD392) compared to hospitals
(USD256). The cost for hospitals ranged from USD239
to USD272 while clinics ranged from USD335 to
USD489. Mzilikazi and Princess Margaret clinics had
Fig. 5 Tas4TB Active TB Case finding pathway, Zimbabwe TDABC, 2018. DC=Demand creation; HIV=Human immune-deficiency virus; DM =
Diabetes mellitus; EHT = Environmental health technician; CXR = Chest X-ray; TB = Tuberculosis; BP=Blood Pressure; Ht = Height; Wt =Weight;
Temp = Temperature; Lab = Laboratory; Pos = Positive; Neg = Negative; Rx = Treatment
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costs of over USD400, due to high unit cost for sample
transportation and HIV testing.
The diagnostic cost was USD69 and treatment cost
was USD255 per patient. Treatment cost ranged from
USD181 to USD387 per patient. The average diagnostic
and treatment costs per patient were 1·2 and 1·7 times
higher in clinics than in hospitals. The average cost of
HIV testing per patient was higher in clinics (USD7)
compared to hospitals (USD3), due to the type of HCW.
The diagnostic costs in clinics were high due to the
transportation of sputum samples from clinics to district
hospitals as well as use of qualified nurses at clinics to
perform HIV testing. Sample processing cost per patient
during treatment stage was higher compared to diagno-
sis stage (USD84 versus USD19). These high costs were
driven by repeat tests during treatment follow-up visits.
Treatment costs were increased by the repeat two
weekly visits to collect anti-TB medication.
Table 7 describes the contribution of each domain to
the total cost of TB diagnosis and treatment. On average
and across all facilities, the major cost drivers were HR
(40%) and laboratory (37%). Cost of diagnosis and treat-
ment of TB was higher in urban clinics compared to
hospitals due to variation in cost of labour. The HR
costs were lower in hospitals USD56 vs USD204 com-
pared to clinics. Laboratory costs were higher in hospi-
tals USD127 vs USD111 in clinics since most of the
laboratory work was hospital based. Nurses working in
urban polyclinics were paid more, contributing to the
higher costs of providing TB services at clinics compared
to hospitals (average USD0·46 vs USD0·08 per minute).
Medical officers from urban clinics were expensive
Table 2 Personnel capacity cost rates by facility by stage, Zimbabwe TDABC, 2018
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compared to district and provincial hospitals average
(USD0·50 vs USD0·16). The overall cost of treatment
was pushed up by the number of follow-up visits to fa-
cilities (of up to six) made by patients. Half of the visits
are only to collect the next 2 weeks of refills, with no
clinical assessment beside vitals.
The costs of targeted active TB screening
Demand creation which precedes TaS4TB screening in-
volves senior level health care workers from national
and provincial levels (Table 5). The diagnosis cost for
TaS4TB was twice that of standard of care, USD153 vs
USD69. Major cost drivers were demand creation, chest
X-ray and sample transportation to nearest diagnostic
facility (USD89, USD33 and USD19 respectively.
Discussion
This study demonstrated that TDABC can be used as a
management tool to understand services’ organisation,
to map and compare resource utilization and cost in a
public health program, and to identify opportunities to
improve care delivery and lower cost. Key success en-
ablers were strong orientation and training at the onset
of the programme, joint development of protocol and
tools, and use of nurses familiar with the TB processes.
Zimbabwe delivers the primary health care with well-
trained HCWs at the lowest level of care to manage the
most common diseases affecting the local population [9].
Nurses in Zimbabwe are trained to manage commonly
occurring diseases, including TB. Additionally, the col-
laboration between local partners, GF and the HBS team
built local capacity for implementation.
We observed minimal variations in the workflow for
treating TB and related comorbid conditions, HIV and
diabetes. Lessons drawn from this study, therefore, can
be applied to the rest of centres that provide TB services.
The urban polyclinics had limited capacity in diagnosing,
yet the volume of patients on treatment was similar to
hospitals [10].
Table 3 Personnel capacity cost rates by facility by stage, Zimbabwe TDABC, 2018
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Treatment cost at urban polyclinics was more expen-
sive than at district and provincial hospitals. Some of
this difference was due to the higher compensation paid
to HCWs in polyclinics, which were supported by the
Ministry of Local Government, compared to the HCWs
in hospitals, supported by the MoHCC. Despite donor
funded retention allowances for rural hospitals, those
HCW salaries were still lower than in urban polyclinics.
The skill-mix also varied between clinics and hospitals.
Higher paid nurses provided TB/HIV counselling care in
urban polyclinics while lower paid lay counsellors pro-
vided these services at hospitals. Hospital staff generally
operated at the top of their license, with nurses deliver-
ing direct patient care and lower-paid staff performing
less-skilled roles. Nurses at clinics, however, performed
multiple functions because of staffing gaps caused by the
inadequate funding for many clinics. Third, hospitals
mainly diagnosed TB patients and then referred them to
clinics for treatment and follow up. Clinic TB diagnostic
costs were 1·2 times higher than at hospitals because of
the high specimen transport costs. HIV testing cost was
also higher in clinics than hospitals, likely due to
task shifting. Hospitals used lay personnel for HIV
testing services while nurses performed HIV testing at
clinics.
Ongoing treatment at clinics involved many steps, in-
cluding bi-weekly treatment follow-ups, recording and
reporting, specimen transportation costs, laboratory
monitoring of treatment response, and medicines pick
up. Zimbabwe could reduce costs by shifting to monthly
follow-up visits, a frequency already used for antiretro-
viral therapy (ART) for HIV patients, and with treatment
outcomes comparable to other low- and middle-income
countries (LMICs) [11].
Table 4 Average observation time in minutes for each stage by facility type, co-morbidity and gender
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Diabetes Mellitus Testing Services (DM) 11.7 (3) 3 (3) 7 (2) 4.4 (7) 6.7 (6) 5.4 (9) 6 (10) 5.8 (5)




















Receiving and Initial registration Sputum
Specimens
























Consultation after Chest X-ray .. .. .. 2.3 (14) 1.8 (6) 2.6 (7) 2.3 (13) 2 (1)
Third Consultation, for sputum negative
presumptive cases
























Chirenda et al. BMC Health Services Research          (2021) 21:242 Page 10 of 16
Table 5 Space and Equipment capacity cost rate, Zimbabwe TDABC, 2018







Waiting room Registration, Vital Signs, Initial Consultation, Recording and reporting 364.5 0.048
Consulting
Room Nursing
Third Consultation sputum negative presumptive cases, Treatment Initiation for DSTB, Initial
Consultation, Second Consultation with sputum results, Sputum sample collection for TB diagnosis,
Medicines Collection, HIV Testing Services, Recording and Reporting, Treatment Follow up DSTB,




Second Consultation with Sputum results, Third Consultation for sputum negative presumptive cases,
Treatment follow up DSTB
54 0.007
Laboratory Sample processing and registration of results, Chest X-Ray 90 0.012




Waiting room Registration, Treatment Follow up DSTB 750 0.098
Consultation
Room
Second Consultation with Sputum results, treatment follow up DSTB 60 0.008
Consulting
Room Nursing
Initial Consultation, Second Consultation with Sputum results, Treatment Initiation DSTB, Treatment





Third consultation for sputum negative presumptive cases 60 0.008
Laboratory Receiving and initial registration of sputum specimens, Treatment Follow up, Sample processing and
registration of results
1108 0.145










Initial Consultation, Second Consultation with Sputum results, Treatment Initiation DSTB, Treatment





Third consultation for sputum negative presumptive cases, Treatment follow up DSTB 10 0.001
Laboratory Receiving and initial registration of sputum specimens, Sample processing and registration of results,
sputum sample transportation
12.6 0.002
Pharmacy Medicines Collection (Anti-TB and Ancillary) 10.25 0.001
X-ray Room Chest X-ray
Maphisa District
Hospital
Waiting room Registration, Vital Signs, Initial Consultation, HIV Testing Services, Treatment follow up 364.5 0.048
Consultation
Room - Nurse
Initial Consultation, Second Consultation with Sputum Results, Sputum sample collection for TB




Initial Consultation, Treatment Initiation DS-TB, Recording and Reporting 54 0.007
Laboratory Receiving and initial registration of sputum specimens, Sample processing and registration of results,
Sputum sample transportation, Recording and Reporting
90 0.012
Pharmacy Medicines Collection (Anti-TB and Ancillary) 90 0.012
Dzivarasekwa
Clinic
Waiting room Registration, Vital Signs, and Treatment follow up 342 0.045
Consultation
Room










Third Consultation for sputum negative presumptive cases 18 0.002
Laboratory Receiving and initial registration of sputum specimens, sample processing and registration of results,
Sputum sample collection for TB diagnosis, Recording and Reporting
16 0.002
Pharmacy Medicines Collection (Anti-TB and Ancillary), Treatment follow up DS-TB 6 0.001
Mzilikazi Clinic Waiting room Registration, Vital Signs, HIV Testing Services, Treatment Follow up 16.8 0.004
Consultation
Room





Initial consultation, Sputum sample collection for TB diagnosis, Second Consultation with sputum
results, Recording and Reporting, Medicines collection (Anti-TB and Ancillary)
29.2 0.004
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The NTP could also conduct a study on the cost-
saving benefits from eliminating repeat sputum micros-
copy tests at the 5th and 6th monthly visits. The study
would assess quality of care, misclassification errors of
cured into treatment completed and proportion of
missed multidrug resistant TB cases post-treatment. The
cost data from this study was used for the 2020–2024
national strategic plan, using the TB/HIV Impact
Measure and Estimates (TIME) modelling tool.
Cost of confirmation at Tas4TB was 2·2 times more
than standard of care due to sample transportation costs
and demand creation. Since Tas4TB was a new concept,
opportunities to improve its efficiency are possible. For
example, reorganising the Tas4TB workflow and reas-
signing of responsibilities from national level to district
health care workers, especially for demand creation,
would lower total costs. Embedding a molecular diag-
nostic equipment in the van used for Tas4TB would also
Table 5 Space and Equipment capacity cost rate, Zimbabwe TDABC, 2018 (Continued)







Third Consultation for sputum negative presumptive cases 15.2 0.002
Laboratory Thorngroove Laboratory 69 0.009
Pharmacy Medicines Collection (Anti-TB and Ancillary), Treatment follow up DS-TB 12 0.002
X-ray Room Khami Clinic
Princess
Margaret Clinic
Waiting room Registration, Vital Signs 41.2 0.005
Consulting
Room Nursing
Initial consultation, second consultation with sputum results, HIV testing services, Sputum sample
collection for TB diagnosis, Treatment Initiation DS-TB, Treatment follow up DS-TB, Recording and




Third Consultation for sputum negative presumptive cases, Treatment follow up DS-TB 13.25 0.002
Laboratory Thorngroove Clinic, Recording and Reporting 69 0.009
Pharmacy 12 0.002
X-ray Room Khami Clinic
Rutsanana Clinic Waiting room Registration, Vital Signs 106 0.014
Consultation
Room
HIV Testing Services, Treatment follow up DS-TB 0.002
Consulting
Room Nursing
Initial consultation, second consultation with sputum results, Treatment initiation DS-TB, Sputum sam-




Sputum sample collection for TB diagnosis 12 0.002
Laboratory Receiving and initial registration of sputum specimens, sample processing and registration of results,
Medicines collection (Anti-TB and Ancillary), Recording and Reporting
14 0.002
Pharmacy Medicines collection (Anti-TB and Ancillary) 12 0.002
Tas4TB Waiting room Registration, Vital Signs, Sputum sample collection for TB diagnosis, Treatment Initiation DS-TB, Medi-




Initial Consultation, Diabetes Mellitus Testing Services, HIV Testing Services 0.004
Consulting
Room Nursing
Initial consultation, HIV Testing Services, Diabetes Mellitus Testing Services, Recording and Reporting,




Initial Consultation, Chest X-Ray, Treatment Initiation DSTB, Doctor’s consultation after CXR 5 0








TB Mobile Van 0·57
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lower costs. Optimising screening by Tas4TB is critical
because studies from Zimbabwe and other countries
have shown that targeting high risk groups increases
access and reduces TB incidence [12, 13].
An inherent limitation of the study, due to it being the
first to use TDABC to measure the cost of TB treatment,
was the inability to compare and learn from treatment
processes and costs in other low-to-medium income
countries. In addition, a more longitudinal study to fol-
low a cohort of patients through diagnosis to treatment
completion would be able to provide more strong
evidence.
Our study results provided data to inform possible
policy changes and cost reductions. The cost of labora-
tory (diagnostic) services could be reduced by redeploy-
ing GeneXpert machines to reduce transport costs and
improve access of TB diagnostic services to patients.
This would require a thorough mapping exercise to as-
sess the current reach of GeneXpert machines. Such a
policy change would increase access for patients, reduce
the cost of transport, and increase the capabilities (re-
sources) and decrease processing time at each facility.
The treatment sites could also batch TB diagnosis sam-
ples with those of disease programmes to optimize
shared costs. Patients’ follow-up visits during treatment
phase could be reduced from 12 to 6 by customizing
drug-refill frequencies to patient risk characteristics. The
reduction would lower provider costs and increase pa-
tient compliance, by removing repetitive process steps
that do not lead to better treatment outcomes.
Conclusion
The study has shown the feasibility of applying and em-
bedding TDABC as a management tool for analysing
and costing care processes in limited-resource public
health programs. The study identified processes that
would benefit from re-engineering, shifts in the skill mix
of personnel used to perform tasks, and unpacked di-
mensions in domestic funding that were not visible. Per-
forming drug refills for co-infected TB/HIV patients on
the same schedule would reduce costs to both providers
and patients. The dimensions of domestic funding that
are not visible in the NSPs are contributions through the
Zimbabwe Ministry of Local Government.
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